5-hydroxytryptophan has been researched along with Intellectual Disability in 15 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Intellectual Disability: Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a patient with the Lesch-Nyhan syndrome we found decreased spinal fluid 5-hydroxyindole acetic acid (5-HIAA), the major metabolite of serotonin, and decreased homovanillic acid (HVA), the major metabolite of dopamine, indicating a decrease in monoamine metabolism." | 7.66 | Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome. ( Castells, S; Chakrabarti, C; Hurwic, M; Nyhan, WL; Perel, JM; Winsberg, BG, 1979) |
| "6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency is the most important type of BH4 deficiency related to hyperphenylalaninemia." | 3.73 | Long-term follow-up of Chinese patients who received delayed treatment for 6-pyruvoyl-tetrahydropterin synthase deficiency. ( Cheng, LY; Chiu, PC; Hsiao, KJ; Lee, NC; Liu, TT; Niu, DM, 2006) |
| "In a patient with the Lesch-Nyhan syndrome we found decreased spinal fluid 5-hydroxyindole acetic acid (5-HIAA), the major metabolite of serotonin, and decreased homovanillic acid (HVA), the major metabolite of dopamine, indicating a decrease in monoamine metabolism." | 3.66 | Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome. ( Castells, S; Chakrabarti, C; Hurwic, M; Nyhan, WL; Perel, JM; Winsberg, BG, 1979) |
| "PAK3-related intellectual disability is caused by mutations in the gene encoding the p21-activated kinase (PAK) protein." | 1.48 | Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome. ( Bartel, T; Blydt-Hansen, I; Connolly, MB; Horvath, GA; Race, S; Ross, CJ; Tarailo-Graovac, M; Van Allen, MI; van Karnebeek, CDM; Wasserman, WW, 2018) |
| "Although phenylketonuria (PKU) is the most common genetic cause of mental retardation, the cellular mechanisms underlying impaired brain function are still unclear." | 1.37 | 5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria. ( Andolina, D; Cabib, S; Conversi, D; Pascucci, T; Puglisi-Allegra, S; Trabalza, A; Ventura, R, 2011) |
| "It is postulated that the seizures and neurological deterioration of the patient were related to a deficiency in the synthesis of biogenic amine neurotransmitters." | 1.26 | Biogenic amine synthesis defect in dihydropteridine reductase deficiency. ( Butler, IJ; Koslow, SH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horvath, GA | 1 |
| Tarailo-Graovac, M | 1 |
| Bartel, T | 1 |
| Race, S | 1 |
| Van Allen, MI | 1 |
| Blydt-Hansen, I | 1 |
| Ross, CJ | 1 |
| Wasserman, WW | 1 |
| Connolly, MB | 1 |
| van Karnebeek, CDM | 1 |
| Andolina, D | 1 |
| Conversi, D | 1 |
| Cabib, S | 1 |
| Trabalza, A | 1 |
| Ventura, R | 1 |
| Puglisi-Allegra, S | 1 |
| Pascucci, T | 1 |
| PERRY, TL | 1 |
| TISCHLER, B | 1 |
| Lee, NC | 1 |
| Cheng, LY | 1 |
| Liu, TT | 1 |
| Hsiao, KJ | 1 |
| Chiu, PC | 1 |
| Niu, DM | 1 |
| Singh, NN | 1 |
| Koslow, SH | 1 |
| Butler, IJ | 1 |
| Castells, S | 1 |
| Chakrabarti, C | 1 |
| Winsberg, BG | 1 |
| Hurwic, M | 1 |
| Perel, JM | 1 |
| Nyhan, WL | 1 |
| Chazot, G | 1 |
| Guard, O | 1 |
| Setiey, A | 1 |
| Robert, JM | 1 |
| Schott, B | 1 |
| Nomura, Y | 1 |
| Segawa, M | 1 |
| Higurashi, M | 1 |
| Bettschart, W | 1 |
| Broché, JP | 1 |
| Tissot, R | 1 |
| Pare, CM | 1 |
| Partington, MW | 1 |
| MacDonald, MR | 1 |
| Airaksinen, EM | 1 |
| Airaksinen, MM | 1 |
| Pentikäinen, P | 1 |
| Hsia, DY | 1 |
| Woolley, DW | 1 |
| Van der Hoeven, T | 1 |
2 reviews available for 5-hydroxytryptophan and Intellectual Disability
| Article | Year |
|---|---|
Current trends in the treatment of self-injurious behavior.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Aged; Ammonia; Aversive Therapy; Behavior Therapy; Child; Ch | 1981 |
Biochemical factors in mental retardation.
Topics: 5-Hydroxytryptophan; Animals; Brain Chemistry; Diet Therapy; Female; Guinea Pigs; Haplorhini; Humans | 1967 |
2 trials available for 5-hydroxytryptophan and Intellectual Disability
| Article | Year |
|---|---|
[Correlation of the clinical and pharmaco-dynamic effects of Niamid in the treatment of severely mentally retarded children].
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Child; Clinical Trials as Topic; Down Syndrome; Female; Huma | 1965 |
5-hydroxytryptophan (5-HTP) in Down's syndrome.
Topics: 5-Hydroxytryptophan; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Female; Human | 1971 |
11 other studies available for 5-hydroxytryptophan and Intellectual Disability
| Article | Year |
|---|---|
Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.
Topics: 5-Hydroxytryptophan; Adolescent; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Intellectual | 2018 |
5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Cognition; Cognition Disorders; Critical Period, Psy | 2011 |
5-HYDROXYTRYPTOPHAN ADMINISTRATION IN PHENYLKETONURIA.
Topics: 5-Hydroxytryptophan; Biomedical Research; Brain; Child; Diet; Electroencephalography; Humans; Indole | 1964 |
Long-term follow-up of Chinese patients who received delayed treatment for 6-pyruvoyl-tetrahydropterin synthase deficiency.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Asian People; Biopterins; Child; Child, Preschool; China; Fe | 2006 |
Biogenic amine synthesis defect in dihydropteridine reductase deficiency.
Topics: 5-Hydroxytryptophan; Biogenic Amines; Carbidopa; Dopamine; Homovanillic Acid; Humans; Hydroxyindolea | 1977 |
Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome.
Topics: 5-Hydroxytryptophan; Amino Acids; Carbidopa; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1979 |
[Ramsay-Hunt syndrome and aniridia in 2 monozygotic twins].
Topics: 5-Hydroxytryptophan; Adolescent; Benzodiazepinones; Blood Group Antigens; Cerebellar Ataxia; Disease | 1975 |
Rett syndrome--an early catecholamine and indolamine deficient disorder?
Topics: 5-Hydroxytryptophan; Adolescent; Basal Ganglia; Catecholamines; Child; Child, Preschool; Droxidopa; | 1985 |
5-hydroxyindoles in phenylketonuric and nonphenylketonuric mental defectives.
Topics: 5-Hydroxytryptophan; Animals; Biological Transport; Carboxy-Lyases; Child; Down Syndrome; Humans; Hy | 1968 |
Fate of 14C-labelled tryptophan and 5-hydroxytryptophan in Down's syndrome.
Topics: 5-Hydroxytryptophan; Administration, Oral; Adolescent; Adult; Autoradiography; Blood Platelets; Carb | 1973 |
Serotonin deficiency in infancy as a cause of a mental defect in experimental phenylketonuria.
Topics: 5-Hydroxytryptophan; Animals; Animals, Newborn; Chlorpromazine; Electroshock; Female; Humans; In Vit | 1965 |